FDA warns: Weight-loss drugs may lead to vision loss

The US Food and Drug Administration (FDA) has directed manufacturers of weight-loss and diabetes medications in the GLP-1 class to add a new safety warning to patient leaflets regarding the risk of sudden vision loss. According to reports by CNBC and Kan 11, the measure was taken after evidence suggested that the use of these drugs may increase the risk of developing a rare eye condition that can lead to blindness. Further details regarding the scope of the reported cases have not yet been released.